The brand-new ACTOnco®+ features a comprehensive testing of 440 cancer-related genes and now provides therapeutic implications for targeted therapy, chemotherapy, hormone therapy and PARP1 inhibitors. ACTOnco®+ covers most of the key signaling pathways related to cancer, identifying more drug options for patients. In addition, ACTOnco®+ uses mutation burden, immune-related gene information and MSI status to provide a more accurate prediction of immunotherapy response.

More details on ACTOnco®+: http://www.aichuangreng.com/en/service/actonco